According to TipRanks.com, Shu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.8% and a 26.6% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cue Biopharma with a $29.50 average price target, representing a 167.9% upside. In a report issued on January 3, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $28.00 price target.
The company has a one-year high of $18.42 and a one-year low of $9.65. Currently, Cue Biopharma has an average volume of 316.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
Read More on CUE:
- Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
- Morgan Stanley Sticks to Their Sell Rating for Editas Medicine (EDIT)
- Morgan Stanley Thinks Galapagos’ Stock is Going to Recover
- Morgan Stanley Sticks to Their Sell Rating for Bluebird Bio (BLUE)
- Sarepta Therapeutics (SRPT) Receives a Hold from Berenberg Bank